- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. Request a Demo or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 834-848 of
1,261 results
2517 Exhibit: EX2517 Merck Provides Update on Combination Medicine JUVISYNC...
Document
IPR2023-00724, No. 2517 Exhibit - EX2517 Merck Provides Update on Combination Medicine JUVISYNC™ sitagliptin and simvastatin Tablets, httpswwwmerckcomnewsmerck provides update on...
|
|
Cite Document
2370 Exhibit: EX2370 White, Jr, JR, A Brief History of the Development of Diabetes...
Document
IPR2023-00724, No. 2370 Exhibit - EX2370 White, Jr, JR, A Brief History of the Development of Diabetes Medications, Diabetes Spectr 201427282 86 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2371 Exhibit: EX2371 US Food Drug Administration, DrugsFDA, Prandin®
Document
IPR2023-00724, No. 2371 Exhibit - EX2371 US Food Drug Administration, DrugsFDA, Prandin® (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2418 Exhibit: EX2418 US Food Drug Administration, DrugsFDA, Bydureon®
Document
IPR2023-00724, No. 2418 Exhibit - EX2418 US Food Drug Administration, DrugsFDA, Bydureon® (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2533 Exhibit: EX2533 Novo Nordisk seeks partners within
Document
IPR2023-00724, No. 2533 Exhibit - EX2533 Novo Nordisk seeks partners within (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
1071 Exhibit: US6284727
Document
IPR2023-00724, No. 1071 Exhibit - US6284727 (P.T.A.B. Mar. 16, 2023)
|
|
Cite Document
1173 Exhibit: Exhibit 1173 Gordon
Document
IPR2023-00724, No. 1173 Exhibit - Exhibit 1173 Gordon (P.T.A.B. May. 22, 2024)
|
|
Cite Document
2434 Exhibit: EX2434 Farxiga® Prescribing Information rev Oct 2017
Document
IPR2023-00724, No. 2434 Exhibit - EX2434 Farxiga® Prescribing Information rev Oct 2017 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2386 Exhibit: EX2386 National Institute for Health and Care Research, “Losing weig...
Document
IPR2023-00724, No. 2386 Exhibit - EX2386 National Institute for Health and Care Research, “Losing weight following type 2 diabetes diagnosis boosts chance of remission,” httpsevidencenihrac...
|
|
Cite Document
2010 Exhibit: EX2010 Expert Declaration of Julio Rosenstock, MD
Document
IPR2023-00724, No. 2010 Exhibit - EX2010 Expert Declaration of Julio Rosenstock, MD (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2098 Exhibit: EX2098 Jha, KK, et al, Transitioning to GLP 1 RAs and SGLT2 Inhibit...
Document
IPR2023-00724, No. 2098 Exhibit - EX2098 Jha, KK, et al, Transitioning to GLP 1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes, Curr Athe...
|
|
Cite Document
2111 Exhibit: EX2111 Verma, S, et al, Effects of glucagon like peptide 1 receptor a...
Document
IPR2023-00724, No. 2111 Exhibit - EX2111 Verma, S, et al, Effects of glucagon like peptide 1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body m...
|
|
Cite Document
2482 Exhibit: EX2482 Novo Nordisk, Possible Side Effects of Ozempic semaglutide...
Document
IPR2023-00724, No. 2482 Exhibit - EX2482 Novo Nordisk, Possible Side Effects of Ozempic semaglutide Injection, httpswwwozempiccomhow to takeside effectshtml (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2377 Exhibit: EX2377 Janssen Pharmaceuticals, Inc, “US FDA Approves INVOKAN...
Document
IPR2023-00724, No. 2377 Exhibit - EX2377 Janssen Pharmaceuticals, Inc, “US FDA Approves INVOKANA™ Canagliflozin for the Treatment of Adults with Type 2 Diabetes,” httpswwwprnewswire...
|
|
Cite Document
1016 Exhibit: US20070010424
Document
IPR2023-00724, No. 1016 Exhibit - US20070010424 (P.T.A.B. Mar. 16, 2023)
|
|
Cite Document
